Sugi Predict

Sugi Predict / Compounds / SCHEMBL4624290

SCHEMBL4624290

SCHEMBL4624290

CC(O)COC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.52
▸ KIF11 P52732 1/20 0.47
▸ MAPK1 P28482 1/20 0.45
▸ TK1 P04183 2/20 0.45
▸ GRIN1 Q05586 6/20 0.40
▸ GRIN2A Q12879 6/20 0.40
▸ GRIN2D O15399 5/20 0.40
▸ GRIN2C Q14957 5/20 0.40
▸ GRIN2B Q13224 4/20 0.40
▸ CTSK P43235 3/20 0.40
▸ DUT P33316 1/20 0.39
▸ CYP2C19 P33261 2/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ CYP1A2 P05177 1/20 0.36
▸ OPRM1 P35372 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20341349 1.00 LMNA (0.52) LMNAKIF11MAPK1TK1GRIN1
SCHEMBL1487205 1.00 LMNA (0.52) LMNAKIF11MAPK1TK1GRIN1
SCHEMBL10434091 0.88 LMNA (0.46) LMNAKIF11KCNH2
SCHEMBL10434128 0.88 LMNA (0.46) LMNAKIF11KCNH2
SCHEMBL24937040 0.88 LMNA (0.46) LMNAKIF11KCNH2
SCHEMBL10419038 0.86 LMNA (0.43) LMNAKIF11MAPK1TK1GRIN1
SCHEMBL18307295 0.85 KIF11 (0.44) LMNAKIF11TK1GRIN1GRIN2A
SCHEMBL16281907 0.83 KIF11 (0.50) LMNAKIF11TK1GRIN1GRIN2A
SCHEMBL10772460 0.83 TK1 (0.54) LMNAKIF11TK1GRIN1GRIN2A
SCHEMBL2111572 0.83 KIF11 (0.50) LMNAKIF11TK1GRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117186145-B Preparation method of glyceraldehyde-3-phosphoric acid 长沙晨辰医药科技有限公司 2024-05-28 — — CN claimed
CN-117186145-A Preparation method of glyceraldehyde-3-phosphoric acid 长沙晨辰医药科技有限公司 2023-12-08 — — CN claimed
US-4943626-A Primary polyether active hydrogen compounds which are prepared from linked, protectively initiated polyalkyleneoxides THE DOW CHEMICAL COMPANY (US) 1990-07-24 — — US claimed
EP-4631938-A1 NITROGEN-CONTAINING HETEROCYCLE WITH SEROTONIN RECEPTOR-BINDING ACTIVITY AND CARBOCYCLIC DERIVATIVE Shionogi & Co., Ltd (JP) 2025-10-15 — — EP disclosed
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2025-04-10 — — US disclosed
US-12157734-B2 Sulfoximine glycosidase inhibitors ASCENEURON SA (CH) 2024-12-03 — — US disclosed
CN-108368040-B Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections 默沙东有限责任公司 2024-08-23 — — CN disclosed
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 — — US disclosed
WO-2024122617-A1 NITROGEN-CONTAINING HETEROCYCLE WITH SEROTONIN RECEPTOR-BINDING ACTIVITY AND CARBOCYCLIC DERIVATIVE 塩野義製薬株式会社 2024-06-13 — — WO disclosed
CN-117186145-B Preparation method of glyceraldehyde-3-phosphoric acid 长沙晨辰医药科技有限公司 2024-05-28 — — CN disclosed
CN-117858881-A Phospholipid compounds and methods of making and using the same 吉利德科学公司 2024-04-09 — — CN disclosed
EP-0781138-B1 LIPID ANALOGS FOR TREATING VIRAL INFECTIONS UNIV WAKE FOREST (US) 2008-05-21 — — EP disclosed
WO-2006024823-A9 PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-03-15 — — WO disclosed
US-20070015943-A1 Method of preparation of optically active alcohols POSTECH FOUNDATION (KR) 2007-01-18 — — US disclosed
WO-2005009935-A1 METHOD OF PREPARATION OF OPTICALLY ACTIVE ALCOHOLS POSTECH FOUNDATION (KR) 2005-02-03 — — WO disclosed
US-5977395-A ALKYLATION RHONE-POULENC CHIMIE (FR) 1999-11-02 — — US disclosed
US-5637722-A ALKYLATION OF NUCLEOPHILE WITH ALKYL PROPARGYL XANTHATE RHONE-POULENC CHIMIE (FR) 1997-06-10 — — US disclosed
WO-1997013743-A1 POLYFUNCTIONAL CATIONIC CYTOFECTINS, FORMULATIONS AND METHODS FOR GENERATING ACTIVE CYTOFECTIN: POLYNUCLEOTIDE TRANSFECTION COMPLEXES UNIV CALIFORNIA (US) 1997-04-17 — — WO disclosed
US-4943626-A Primary polyether active hydrogen compounds which are prepared from linked, protectively initiated polyalkyleneoxides THE DOW CHEMICAL COMPANY (US) 1990-07-24 — — US disclosed
EP-0352819-A2 Primary polyether active hydrogen compounds and process for preparing the same THE DOW CHEMICAL COMPANY (US) 1990-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157734-B2 Sulfoximine glycosidase inhibitors ENGASE, BACE1, GAA LMNA 1834/4885KIF11 3510/4885MAPK1 4229/4885
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, PARK7, PINK1 LMNA 2450/4885KIF11 1526/4885MAPK1 117/4885
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ENGASE, BACE1, GAA LMNA 1721/4885KIF11 3575/4885MAPK1 4170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.